CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin combines a GHRH analog with a selective GH-secretagogue-receptor agonist to push the body's own pulsatile GH and IGF-1 higher. Each peptide has some early human data, but the blend lacks controlled proof, sells as a research chemical, and is WADA-banned in sport. Educational, not medical advice.

Start free →Dose tools

Category	Growth Hormone
Regulatory status	Not FDA-approved, individually or as a blend.

Mechanism

A commonly combined pair of growth hormone secretagogues: CJC-1295 (a GHRH analog that stimulates GH release; with or without the DAC long-acting modification) and ipamorelin (a selective ghrelin/GH-secretagogue-receptor agonist). Together they aim to amplify pulsatile endogenous GH/IGF-1 release.

Half-life

Ipamorelin short (~2 hours); CJC-1295 without DAC short (~30 min), with DAC markedly longer (days). Combined regimens vary accordingly. Commonly reported use/dosing: No approved protocol. Reported anecdotal use is subcutaneous injection of both peptides (often before sleep), in microgram doses over cycles; not a clinically validated regimen.

Regulatory status

Not FDA-approved, individually or as a blend. These peptides are not approved drugs in the US and are sold as research chemicals; GH secretagogues are prohibited in sport (WADA).

Safety

Reported effects include water retention, flushing, headache, injection-site reactions, and increased hunger (ghrelin agonism); raising GH/IGF-1 carries theoretical risks (insulin resistance, tumor growth). Research-grade purity concerns; prohibited in sport.

Evidence

Individual peptides have some early human pharmacology data, but the combination lacks robust controlled clinical evidence; not clinically validated.

Sources

Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999;16(9):1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/
Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
Bowers CY, et al. GH-releasing peptide stimulates GH release and acts synergistically with GHRH. J Clin Endocrinol Metab. 1990;70(4):975-982. https://pubmed.ncbi.nlm.nih.gov/2108187/
Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143. https://pubmed.ncbi.nlm.nih.gov/10990150/

PepWise is an informational and educational tracking tool, not medical advice and not a medical device. CJC-1295 + Ipamorelin may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.